Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

Related Keywords

United States ,American ,Vaishali Sanchorawala ,Heather Landau ,Jeffrey Zonder ,Peer Exchange ,American Society Of Hematology ,American Society ,Light Chain Amyloidosis ,Al Amyloidosis ,Andromeda ,Daratumumab ,Vital ,Pronto ,Affirm Al ,Nexicart 1 ,Amyloid Deposits ,Cd 38 Directed Monoclonal Antibodies ,Cardiac Involvement ,Mayo Cardiac Staging ,Stem Cell Transplant ,Remission ,Duration Of Therapy ,Diagnosis ,Unmet Needs ,Managing Al Amyloidosis ,Treating Al Amyloidosis ,Nxc 201 ,Cart Therapy ,Amyloidosis Diagnosis ,Prognosis ,Mortality ,